Skip to content
The Nexus
HEALTHJul 20 · 18:45 UTCMEDPAGE TODAY

Second Season of Clesrovimab for RSV Well Tolerated in High-Risk Kids

The long-acting monoclonal antibody clesrovimab (Enflonsia) was well tolerated in high-risk infants during two RSV seasons, according to a randomized clinical trial. The drug is used for RSV prevention in infants at increased risk for severe disease.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
ClesrovimabtopicEnflonsiatopicRespiratory Syncytial VirustopicMedPage Todayorganizationinfants at increased risk for severe diseasetopicrandomized clinical trialtopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting